Q-omics provides the consensus-scored COX7B2 profile across patient tissues and cancer cell-line models. COX7B2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, COX7B2 is differentially expressed in 4, with the highest sampling consensus in LIHC. Additionally, COX7B2 RNA expression shows 7,694 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, LIHC, and TGCT as cancer lineages where COX7B2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX7B2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX7B2 survival associations across molecular data types. COX7B2 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX7B2 RNA expression–survival associations across cancer types. High COX7B2 expression shows unfavorable associations in BRCA, KIRP, KICH, CHOL and KIRC, but favorable associations in UCS. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for COX7B2 RNA expression.
This table summarizes COX7B2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for COX7B2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX7B2 shows higher tumor expression in LIHC, LUSC, BRCA and LUAD. The LIHC box plot shows higher COX7B2 RNA expression in tumor versus normal tissue (log2 FC = +2.467, t-test p < 0.001).
This table shows molecular features associated with COX7B2 in patient tissues and cancer cell lines. In patient samples, COX7B2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, COX7B2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
